MCID: MST002
MIFTS: 51

Mast-Cell Leukemia

Categories: Cancer diseases, Immune diseases

Aliases & Classifications for Mast-Cell Leukemia

MalaCards integrated aliases for Mast-Cell Leukemia:

Name: Mast-Cell Leukemia 12 14
Leukemia, Mast-Cell 41 69
Mast Cell Leukemia 36 28
Leukemia Mast Cell 51

Classifications:



External Ids:

Disease Ontology 12 DOID:9254
ICD10 32 C94.3 C94.30
MeSH 41 D007946
NCIt 46 C3169
KEGG 36 H01511
UMLS 69 C0023461

Summaries for Mast-Cell Leukemia

Disease Ontology : 12 A leukemia that results_in an overwhelming number of tissue mast cells located in peripheral blood.

MalaCards based summary : Mast-Cell Leukemia, also known as leukemia, mast-cell, is related to systemic mastocytosis and aggressive systemic mastocytosis. An important gene associated with Mast-Cell Leukemia is KIT (KIT Proto-Oncogene Receptor Tyrosine Kinase), and among its related pathways/superpathways are PI3K-Akt signaling pathway and ERK Signaling. The drugs Ketamine and Iron have been mentioned in the context of this disorder. Affiliated tissues include peripheral blood, myeloid and bone marrow, and related phenotypes are Decreased viability and Decreased viability

Wikipedia : 72 Mast cell leukemia is an extremely aggressive subtype of acute myeloid leukemia that usually occurs de... more...

Related Diseases for Mast-Cell Leukemia

Diseases related to Mast-Cell Leukemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 53)
# Related Disease Score Top Affiliating Genes
1 systemic mastocytosis 32.4 KIT KITLG
2 aggressive systemic mastocytosis 30.4 KIT KITLG
3 urticaria pigmentosa 30.2 KIT KITLG
4 cutaneous mastocytosis 29.9 ATP7A KIT KITLG
5 asthma 29.1 CCL2 CCL5 KITLG RASGRP4
6 aleukemic mast cell leukemia 12.3
7 classic mast cell leukemia 12.2
8 leukemia 10.7
9 indolent systemic mastocytosis 10.4 KIT KITLG
10 cutaneous solitary mastocytoma 10.4 KIT KITLG
11 ewing's family of tumors 10.4 KIT KITLG
12 dowling-degos disease 1 10.3 KIT KITLG
13 diffuse cutaneous mastocytosis 10.3 ATP7A KIT
14 stachybotrys chartarum 10.3 CCL2 CCL5
15 radiculopathy 10.2 CCL2 CCL5
16 congenital mesoblastic nephroma 10.2 KIT NTRK3
17 viral encephalitis 10.2 CCL2 CCL5
18 polymorphous low-grade adenocarcinoma 10.2 KIT NTRK3
19 viral meningitis 10.2 CCL2 CCL5
20 piebald trait 10.2 KIT KITLG
21 malignant mesenchymoma 10.1 KIT NTRK3
22 myeloid leukemia 10.1
23 pulmonary vein stenosis 10.0 KDR KIT
24 senile angioma 10.0 KDR KIT
25 mast cell neoplasm 10.0 KIT KITLG NTRK3
26 leukemia, acute myeloid 10.0
27 gastrointestinal stromal tumor 10.0 KIT KITLG NTRK3
28 8p11 myeloproliferative syndrome 10.0 KDR KIT
29 fibrosarcoma of bone 10.0 KDR KIT
30 mast cell disease 9.9
31 chronic myelomonocytic leukemia 9.9
32 pdgfrb-associated chronic eosinophilic leukemia 9.9
33 connective tissue cancer 9.9 KIT NTRK3
34 neurofibroma 9.9 KIT KITLG
35 vascular cancer 9.9 KDR KIT
36 leukemia, chronic lymphocytic 2 9.8
37 leukemia, chronic lymphocytic 9.8
38 reticulum cell sarcoma 9.8
39 episodic pain syndrome, familial, 1 9.8
40 hematopoietic stem cell transplantation 9.8
41 portal hypertension 9.8
42 sarcoma 9.8
43 urticaria 9.8
44 histiocytosis 9.8
45 sm-ahnmd 9.8
46 monocytic leukemia 9.8
47 leukemia, b-cell, chronic 9.8
48 back pain 9.8
49 xp22.13p22.2 duplication syndrome 9.8
50 xq12-q13.3 duplication syndrome 9.8

Graphical network of the top 20 diseases related to Mast-Cell Leukemia:



Diseases related to Mast-Cell Leukemia

Symptoms & Phenotypes for Mast-Cell Leukemia

GenomeRNAi Phenotypes related to Mast-Cell Leukemia according to GeneCards Suite gene sharing:

25 (show all 32)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00221-A-1 10.07 KDR BTK KIT CCL2
2 Decreased viability GR00221-A-2 10.07 NTRK3 KDR BTK
3 Decreased viability GR00221-A-3 10.07 KDR BTK
4 Decreased viability GR00221-A-4 10.07 NTRK3 KDR BTK CCL2
5 Decreased viability GR00301-A 10.07 BTK KIT
6 Increased shRNA abundance (Z-score > 2) GR00366-A-100 9.84 SYT1
7 Increased shRNA abundance (Z-score > 2) GR00366-A-102 9.84 BTK KIT
8 Increased shRNA abundance (Z-score > 2) GR00366-A-118 9.84 SYT1
9 Increased shRNA abundance (Z-score > 2) GR00366-A-124 9.84 BTK
10 Increased shRNA abundance (Z-score > 2) GR00366-A-125 9.84 KDR
11 Increased shRNA abundance (Z-score > 2) GR00366-A-126 9.84 SYT1
12 Increased shRNA abundance (Z-score > 2) GR00366-A-130 9.84 NTRK3
13 Increased shRNA abundance (Z-score > 2) GR00366-A-137 9.84 BTK NTRK3
14 Increased shRNA abundance (Z-score > 2) GR00366-A-140 9.84 BTK
15 Increased shRNA abundance (Z-score > 2) GR00366-A-152 9.84 NTRK3 KIT
16 Increased shRNA abundance (Z-score > 2) GR00366-A-157 9.84 KIT
17 Increased shRNA abundance (Z-score > 2) GR00366-A-162 9.84 SYT1
18 Increased shRNA abundance (Z-score > 2) GR00366-A-170 9.84 KIT
19 Increased shRNA abundance (Z-score > 2) GR00366-A-183 9.84 SYT1
20 Increased shRNA abundance (Z-score > 2) GR00366-A-29 9.84 BTK
21 Increased shRNA abundance (Z-score > 2) GR00366-A-30 9.84 NTRK3 KIT
22 Increased shRNA abundance (Z-score > 2) GR00366-A-32 9.84 KDR
23 Increased shRNA abundance (Z-score > 2) GR00366-A-4 9.84 BTK
24 Increased shRNA abundance (Z-score > 2) GR00366-A-41 9.84 NTRK3
25 Increased shRNA abundance (Z-score > 2) GR00366-A-42 9.84 NTRK3 KIT
26 Increased shRNA abundance (Z-score > 2) GR00366-A-73 9.84 BTK
27 Increased shRNA abundance (Z-score > 2) GR00366-A-85 9.84 SYT1 BTK KIT NTRK3 KDR
28 Increased shRNA abundance (Z-score > 2) GR00366-A-9 9.84 KIT
29 Increased shRNA abundance (Z-score > 2) GR00366-A-99 9.84 KIT
30 Decreased substrate adherent cell growth GR00193-A-1 9.63 BTK KIT
31 Decreased substrate adherent cell growth GR00193-A-2 9.63 KIT
32 Decreased substrate adherent cell growth GR00193-A-4 9.63 KDR BTK KIT

MGI Mouse Phenotypes related to Mast-Cell Leukemia:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.87 RASGRP4 SYT1 BTK CCL5 KDR KIT
2 immune system MP:0005387 9.86 ATP7A BTK CCL2 CCL5 KDR KIT
3 liver/biliary system MP:0005370 9.55 SYT1 ATP7A KDR KIT KITLG
4 pigmentation MP:0001186 9.26 ATP7A KIT KITLG RASGRP4
5 respiratory system MP:0005388 9.02 SYT1 ATP7A KDR KIT NTRK3

Drugs & Therapeutics for Mast-Cell Leukemia

Drugs for Mast-Cell Leukemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 152)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
2
Iron Approved Phase 3,Phase 2,Phase 1 7439-89-6 23925
3
Darbepoetin alfa Approved, Investigational Phase 3,Phase 2 209810-58-2, 11096-26-7
4
Ginseng Approved, Investigational, Nutraceutical Phase 3 50647-08-0
5 Analgesics Phase 3,Phase 2
6 Central Nervous System Depressants Phase 3,Phase 2,Phase 1
7 Neurotransmitter Agents Phase 3,Phase 2
8 Anesthetics Phase 3,Phase 2
9 Anesthetics, Dissociative Phase 3
10 Anesthetics, General Phase 3
11 Anesthetics, Intravenous Phase 3
12 Peripheral Nervous System Agents Phase 3,Phase 2
13 Excitatory Amino Acid Antagonists Phase 3
14 Excitatory Amino Acids Phase 3
15 ferric gluconate Phase 3
16 Ferric Compounds Phase 3
17 Narcotics Phase 3
18 Hematinics Phase 3,Phase 2
19 Analgesics, Opioid Phase 3
20 Iron Supplement Nutraceutical Phase 3
21
Sunitinib Approved, Investigational Phase 2,Phase 1 341031-54-7, 557795-19-4 5329102
22
Doxorubicin Approved, Investigational Phase 1, Phase 2 23214-92-8 31703
23
Methotrexate Approved Phase 2 1959-05-2, 59-05-2 126941
24
Mycophenolic acid Approved Phase 2,Phase 1 24280-93-1 446541
25
Mycophenolate mofetil Approved, Investigational Phase 2,Phase 1 128794-94-5 5281078
26
Acetaminophen Approved Phase 2 103-90-2 1983
27
Fludarabine Approved Phase 2,Phase 1 21679-14-1, 75607-67-9 30751
28
Vidarabine Approved, Investigational Phase 2,Phase 1 24356-66-9 21704 32326
29
Busulfan Approved, Investigational Phase 2 55-98-1 2478
30
Histamine Approved, Investigational Phase 2 51-45-6, 75614-87-8 774
31
rituximab Approved Phase 2 174722-31-7 10201696
32
Hydrocortisone Approved, Vet_approved Phase 2 50-23-7 657311 5754
33
Bortezomib Approved, Investigational Phase 1, Phase 2 179324-69-7 387447 93860
34
Prednisolone Approved, Vet_approved Phase 2 50-24-8 5755
35
Miconazole Approved, Investigational, Vet_approved Phase 2,Phase 1 22916-47-8 4189
36
Diphenhydramine Approved, Investigational Phase 2 58-73-1, 147-24-0 3100
37
alemtuzumab Approved, Investigational Phase 2 216503-57-0
38
Granisetron Approved, Investigational Phase 2 109889-09-0 3510
39
Lenograstim Approved, Investigational Phase 2 135968-09-1
40
Denileukin diftitox Approved, Investigational Phase 2 173146-27-5
41
Benzocaine Approved, Investigational Phase 2 1994-09-7, 94-09-7 2337
42
Promethazine Approved, Investigational Phase 2 60-87-7 4927
43
Methylprednisolone Approved, Vet_approved Phase 2 83-43-2 6741
44
Deferasirox Approved, Investigational Phase 2 201530-41-8 5493381
45
Levoleucovorin Approved, Investigational Phase 2 68538-85-2
46
leucovorin Approved, Nutraceutical Phase 2,Phase 1,Early Phase 1 58-05-9 143 6006
47 tannic acid Approved, Nutraceutical Phase 2
48
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2,Phase 1,Early Phase 1 59-30-3 6037
49 Staurosporine Experimental Phase 2 62996-74-1
50
Butyric Acid Experimental, Investigational Phase 2 107-92-6 264

Interventional clinical trials:

(show top 50) (show all 55)

# Name Status NCT ID Phase Drugs
1 Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain Unknown status NCT01316744 Phase 3 ketamine hydrochloride
2 Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical Trial Completed NCT00750009 Phase 3
3 American Ginseng in Treating Patients With Fatigue Caused by Cancer Completed NCT00719563 Phase 3 American ginseng
4 Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain Completed NCT00666211 Phase 3
5 Darbepoetin Alfa With or Without Iron in Treating Anemia Caused By Chemotherapy in Patients With Cancer Completed NCT00661999 Phase 3 sodium ferric gluconate complex in sucrose
6 Midostaurin in Indolent Systemic Mastocytosis Unknown status NCT01920204 Phase 2 Midostaurin,
7 Sunitinib® in Patients With Recurrent Ovarian Clear Cell Carcinoma Unknown status NCT01824615 Phase 2 Sunitinib
8 Brentuximab Vedotin in Treating Patients With Advanced Systemic Mastocytosis or Mast Cell Leukemia Completed NCT01807598 Phase 2 brentuximab vedotin
9 Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies Completed NCT01273766 Phase 2 deferasirox
10 Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer Completed NCT00118352 Phase 2 fludarabine phosphate;cyclosporine;mycophenolate mofetil
11 Ontak (Denileukin Diftitox) in Patients With Systemic Mastocytosis (SM) Completed NCT00493129 Phase 2 Ontak (Denileukin Diftitox)
12 Donor Natural Killer Cells After Donor Stem Cell Transplant in Treating Patients With Advanced Cancer Completed NCT00823524 Phase 1, Phase 2
13 Donor Stem Cell Transplant After Busulfan, Fludarabine, and Antithymocyte Globulin in Treating Patients With Hematological Cancer Completed NCT00627666 Phase 2 busulfan;fludarabine phosphate;leucovorin calcium;methotrexate
14 Epoetin Alfa or Darbepoetin Alfa in Treating Patients With Anemia Caused by Chemotherapy Completed NCT00416624 Phase 2 darbepoetin alfa;epoetin alfa
15 Doxorubicin Hydrochloride Liposome and Bortezomib in Treating Patients With Refractory Hematologic Cancer or Malignant Solid Tumor or Metastatic Breast Cancer Completed NCT00237627 Phase 1, Phase 2 PS-341;Doxil;Velcade
16 Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases Completed NCT00154388 Phase 2 Imatinib mesylate
17 Phase 2 Trial of Prophylactic Rituximab Therapy for Prevention of CGVHD Completed NCT00186628 Phase 2 Rituximab;Anti-thymoglobulin, rabbit (ATG, rabbit ATG);Cyclosporine;Mycophenylate mofetil;Filgrastim;Granisetron;Solumedrol;Acetaminophen;Diphenhydramine;Hydrocortisone
18 Efficacy and Safety of Midostaurin in Patients With Aggressive Systemic Mastocytosis or Mast Cell Leukemia Active, not recruiting NCT00782067 Phase 2 Midostaurin (PKC412)
19 Phase II Midostaurin in Aggressive Systemic Mastocytosis and Mast Cell Leukemia Active, not recruiting NCT00233454 Phase 2 Midostaurin
20 Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic Cancer Active, not recruiting NCT00006251 Phase 1, Phase 2 fludarabine phosphate;cyclosporine;mycophenolate mofetil
21 CD16/IL-15/CD33 Tri-Specific Killer Engagers (TriKes) for CD33+ Hem Malignancies Not yet recruiting NCT03214666 Phase 1, Phase 2 161533 with Bolus Test Dose;161533 Only
22 Ibrutinib in Treating Patients With Advanced Systemic Mastocytosis Terminated NCT02415608 Phase 2 Ibrutinib
23 Sunitinib in Treating Patients With Idiopathic Myelofibrosis Terminated NCT00387426 Phase 2 sunitinib malate
24 Antimicrobial Solution or Saline Solution in Maintaining Catheter Patency and Preventing Catheter-Related Blood Infections in Patients With Malignancies Withdrawn NCT01101412 Phase 1, Phase 2 Edetate Calcium Disodium;Ethanol;Trimethoprim-sulfamethoxazole
25 MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia Completed NCT01231919 Phase 1 Akt inhibitor MK2206
26 Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy Completed NCT00890747 Phase 1 sunitinib malate
27 Quality of Life in Younger Leukemia and Lymphoma Survivors Completed NCT00956475 Phase 1
28 Study of BLU-285 in Patients With Advanced Systemic Mastocytosis (advSM) and Relapsed or Refractory Myeloid Malignancies Recruiting NCT02561988 Phase 1 Avapritinib
29 A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies Recruiting NCT02571036 Phase 1 DCC-2618
30 Study of Information Received About Fertility and Infertility in Patients Who Have Finished Treatment for Cancer Unknown status NCT01295463
31 Collecting Tissue Samples From Patients With Leukemia or Other Blood Disorders Planning to Enroll in an ECOG Leukemia Treatment Clinical Trial Unknown status NCT00897767
32 Magnetic Acupressure in Reducing Pain in Cancer Patients Undergoing Bone Marrow Aspiration and Biopsy Unknown status NCT00670917
33 Patient-Reported Outcome Questionnaire for Systemic Mastocytosis Completed NCT02380222
34 Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant Completed NCT01199562 ganciclovir;valganciclovir;foscarnet sodium
35 Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer Completed NCT00112593 fludarabine phosphate;cyclosporine;mycophenolate mofetil
36 S9007, Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers Completed NCT00996047
37 Methemoglobinemia in Young Patients With Hematologic Cancer or Aplastic Anemia Treated With Dapsone Completed NCT00993694 chemotherapy;dapsone
38 Decision Making About Participating in Pharmacokinetic Studies in Patients Enrolled in a Phase I Treatment Clinical Trial Completed NCT00890435
39 Music in Reducing Anxiety and Pain in Adult Patients Undergoing Bone Marrow Biopsy for Hematologic Cancers or Other Diseases Completed NCT00376922
40 Mast Cell Connect: A Registry for Patients With Mastocytosis Recruiting NCT02620254
41 Registry of Older Patients With Cancer Recruiting NCT01137825
42 Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer Recruiting NCT01137643
43 3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer Recruiting NCT00935090
44 Bioelectrical Impedance Measurement for Predicting Treatment Outcome in Patients With Newly Diagnosed Acute Leukemia Active, not recruiting NCT01869777
45 Massage Therapy Given by Caregiver in Treating Quality of Life of Young Patients Undergoing Treatment for Cancer Active, not recruiting NCT01053494
46 Collecting and Storing Malignant, Borderline Malignant Neoplasms, and Related Samples From Young Patients With Cancer Active, not recruiting NCT00898079
47 Fludarabine Phosphate and Total-Body Radiation Followed by Donor Peripheral Blood Stem Cell Transplant and Immunosuppression in Treating Patients With Hematologic Malignancies Active, not recruiting NCT00014235 fludarabine phosphate;cyclosporine;mycophenolate mofetil
48 Pemetrexed Disodium in the Cerebrospinal Fluid of Patients With Leptomeningeal Metastases Active, not recruiting NCT00424242 Early Phase 1 Pemetrexed
49 Influenza Vaccine in Preventing Flu in Patients Who Have Undergone Stem Cell Transplant and in Healthy Volunteers Terminated NCT00952185
50 Studying Fentanyl in Patients With Cancer Terminated NCT00899951 fentanyl citrate

Search NIH Clinical Center for Mast-Cell Leukemia

Cochrane evidence based reviews: leukemia, mast-cell

Genetic Tests for Mast-Cell Leukemia

Genetic tests related to Mast-Cell Leukemia:

# Genetic test Affiliating Genes
1 Mast Cell Leukemia 28

Anatomical Context for Mast-Cell Leukemia

The Foundational Model of Anatomy Ontology organs/tissues related to Mast-Cell Leukemia:

18
Peripheral Blood

MalaCards organs/tissues related to Mast-Cell Leukemia:

38
Myeloid, Bone Marrow, Bone, Testes, Monocytes

Publications for Mast-Cell Leukemia

Articles related to Mast-Cell Leukemia:

(show top 50) (show all 72)
# Title Authors Year
1
Infliction of proteotoxic stresses by impairment of the unfolded protein response or proteasomal inhibition as a therapeutic strategy for mast cell leukemia. ( 29423023 )
2018
2
KIT D816V- chronic myelomonocytic leukemia progressing to KIT D816V+ associated to mast cell leukemia responding to allogeneic hematopoietic cell transplantation. ( 29151134 )
2018
3
Acute Mast Cell Leukemia Associated with t(4;5)(q21;q33). ( 28412213 )
2017
4
Highly Aggressive de novo Aleukemic Variant of Mast Cell Leukemia Without KIT D816V Mutation. ( 28840997 )
2017
5
Myelodysplasia and Mast Cell Leukemia with t(9;22). ( 29318069 )
2017
6
From the observation of atypical cells on blood smear to the diagnosis of mast cell leukemia: a case report in a 79 year old woman consulting for anemia. ( 29043985 )
2017
7
Aleukemic mast cell leukemia associated with chronic myelomonocytic leukemia and chronic lymphocytic leukemia. ( 29122774 )
2017
8
The clinical and molecular diversity of mast cell leukemia with or without associated hematologic neoplasm. ( 28255023 )
2017
9
Mast cell leukemia (MCL): Clinico-pathologic and molecular features and survival outcome. ( 28599188 )
2017
10
Extramedullary Involvement of Mast Cell Leukemia Detected by 18F-FDG PET/CT. ( 26975014 )
2016
11
Complete response to gemtuzumab ozogamicin in a patient with refractory mast cell leukemia. ( 26876592 )
2016
12
A scientific treatment approach for acute mast cell leukemia: using a strategy based on next-generation sequencing data. ( 27104187 )
2016
13
Application of next generation sequencing in the diagnosis and management of mast cell leukemia. ( 27104182 )
2016
14
Identification of bromodomain-containing protein-4 as a novel marker and epigenetic target in mast cell leukemia. ( 26055303 )
2015
15
De novo leukemic variant of mast cell leukemia with KIT D816V. ( 25729733 )
2015
16
Chronic mast cell leukemia: a novel leukemia-variant with distinct morphological and clinical features. ( 25443885 )
2015
17
FLAG-induced remission in a patient with acute mast cell leukemia (MCL) exhibiting t(7;10)(q22;q26) and KIT D816H. ( 24596674 )
2014
18
Mast cell leukemia with prolonged survival on PKC412/midostaurin. ( 25031773 )
2014
19
Chronic mast cell leukemia (MCL) with KIT S476I: a rare entity defined by leukemic expansion of mature mast cells and absence of organ damage. ( 25209843 )
2014
20
Mast cell leukemia associated with undefined morphology and chronic basophilic leukemia. ( 25264491 )
2014
21
Mast cell leukemia: an extremely rare disease. ( 25028296 )
2014
22
Refined diagnostic criteria and classification of mast cell leukemia (MCL) and myelomastocytic leukemia (MML): a consensus proposal. ( 24675021 )
2014
23
Sustained paranoid psychosis in a patient with mast cell leukemia and decreased serotonin level. ( 23793328 )
2013
24
A case of de novo aleukemic mast cell leukemia without c-KIT mutations in exons 8 and 17. ( 24034180 )
2013
25
A case of systemic mastocytosis associated with acute myeloid leukemia terminating as aleukemic mast cell leukemia after allogeneic hematopoietic stem cell transplantation. ( 23483057 )
2013
26
The transcriptome of the human mast cell leukemia cells HMC-1.2: an approach to identify specific changes in the gene expression profile in KitD816V systemic mastocytosis. ( 23504229 )
2013
27
Mast cell leukemia. ( 23243287 )
2013
28
Mast-cell leukemia exome sequencing reveals a mutation in the IgE mast-cell receptor I^ chain and KIT V654A. ( 22173243 )
2012
29
Systemic mastocytosis: progressive evolution of an occult disease into fatal mast cell leukemia: unique findings on an unusual hematological neoplasm. ( 22661384 )
2012
30
Aleukemic variant of mast cell leukemia. ( 22482127 )
2012
31
Mast cell leukemia: identification of a new c-Kit mutation, dup(501-502), and response to masitinib, a c-Kit tyrosine kinase inhibitor. ( 22324351 )
2012
32
Death from mast cell leukemia: a young patient with longstanding cutaneous mastocytosis evolving into fatal mast cell leukemia. ( 22329485 )
2012
33
Aberrant expression of CD30 in aggressive systemic mastocytosis and mast cell leukemia: a differential diagnosis to consider in aggressive hematopoietic CD30-positive neoplasms. ( 21261503 )
2011
34
The classification of systemic mastocytosis should include mast cell leukemia (MCL) and systemic mastocytosis with a clonal hematologic non-mast cell lineage disease (SM-AHNMD). ( 20688965 )
2010
35
Inhibition of JAK-STAT signaling by TG101348: a novel mechanism for inhibition of KITD816V-dependent growth in mast cell leukemia cells. ( 20485374 )
2010
36
Myelomastocytic leukemia versus mast cell leukemia versus systemic mastocytosis associated with acute myeloid leukemia: a diagnostic challenge. ( 20658589 )
2010
37
Mast cell leukemia with rapidly progressing portal hypertension. ( 19883434 )
2009
38
KIT regulates tyrosine phosphorylation and nuclear localization of beta-catenin in mast cell leukemia. ( 17949810 )
2008
39
Mast cell leukemia: a report of ten cases. ( 18172645 )
2008
40
Establishment of a murine model of aggressive systemic mastocytosis/mast cell leukemia. ( 16543062 )
2006
41
Expression of a constitutively active mutant of M-Ras in normal bone marrow is sufficient for induction of a malignant mastocytosis/mast cell leukemia, distinct from the histiocytosis/monocytic leukemia induced by expression of activated H-Ras. ( 15735740 )
2005
42
Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation. ( 15972446 )
2005
43
Cladribine therapy in a patient with an aleukemic subvariant of mast cell leukemia. ( 15928938 )
2005
44
Aleukemic mast cell leukemia with abnormal immunophenotype and c-kit mutation D816V. ( 15512820 )
2004
45
Induction of apoptosis in the human mast cell leukemia cell line HMC-1 by various antineoplastic drugs. ( 12688323 )
2003
46
Malignant hematopoietic cell lines: in vitro models for the study of mast cell leukemia. ( 12801523 )
2003
47
Mast cell leukemia. ( 12564414 )
2003
48
Rapid engraftment of mast cells of donor origin in a case of acute myeloid leukemia with mast cell leukemia after allogeneic stem cell transplantation. ( 12815487 )
2003
49
Mast cell leukemia--a rare form of myeloid leukemia. ( 12238304 )
2002
50
Low back pain and myalgias in acute and relapsed mast cell leukemia: a case report. ( 12048668 )
2002

Variations for Mast-Cell Leukemia

Expression for Mast-Cell Leukemia

Search GEO for disease gene expression data for Mast-Cell Leukemia.

Pathways for Mast-Cell Leukemia

Pathways related to Mast-Cell Leukemia according to KEGG:

36
# Name Kegg Source Accession
1 PI3K-Akt signaling pathway hsa04151

Pathways related to Mast-Cell Leukemia according to GeneCards Suite gene sharing:

(show all 18)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.49 BTK CCL2 CCL5 KDR KIT KITLG
2
Show member pathways
13.28 BTK CCL2 CCL5 KDR KIT KITLG
3
Show member pathways
13.15 BTK CCL2 CCL5 KDR KIT KITLG
4
Show member pathways
13.08 CCL2 CCL5 KIT KITLG RASGRP4
5
Show member pathways
13.04 BTK KDR KIT KITLG NTRK3
6
Show member pathways
12.95 BTK CCL2 CCL5 KDR KIT KITLG
7
Show member pathways
12.75 BTK KDR KIT KITLG NTRK3
8
Show member pathways
12.71 CCL2 KDR KIT KITLG NTRK3
9
Show member pathways
12.56 BTK CCL2 CCL5 KDR KIT KITLG
10 12.49 KDR KIT KITLG RASGRP4
11
Show member pathways
12.45 KDR KIT KITLG RASGRP4
12 12.07 BTK CCL2 CCL5 KIT KITLG
13
Show member pathways
11.92 BTK KIT KITLG
14 11.79 BTK KDR KIT KITLG
15 11.19 KIT KITLG
16 10.95 BTK CCL2 CCL5
17 10.7 KIT KITLG
18 10.07 BTK CCL2 CCL5 KDR KIT KITLG

GO Terms for Mast-Cell Leukemia

Cellular components related to Mast-Cell Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 plasma membrane GO:0005886 9.76 ATP7A BTK KDR KIT KITLG NTRK3
2 cytoplasm GO:0005737 9.61 ATP7A BTK CCL5 KDR KIT KITLG
3 membrane raft GO:0045121 9.43 ATP7A BTK KDR
4 mast cell granule GO:0042629 8.62 BTK KIT

Biological processes related to Mast-Cell Leukemia according to GeneCards Suite gene sharing:

(show all 25)
# Name GO ID Score Top Affiliating Genes
1 phosphorylation GO:0016310 9.92 BTK KDR KIT NTRK3
2 positive regulation of cell proliferation GO:0008284 9.88 KDR KIT KITLG NTRK3
3 protein phosphorylation GO:0006468 9.85 BTK CCL2 KDR KIT NTRK3
4 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.76 CCL2 CCL5 KDR
5 regulation of cell shape GO:0008360 9.72 CCL2 KDR KIT
6 positive regulation of cell migration GO:0030335 9.71 CCL5 KDR KIT NTRK3
7 cell chemotaxis GO:0060326 9.65 CCL2 CCL5 KIT
8 monocyte chemotaxis GO:0002548 9.62 CCL2 CCL5
9 protein autophosphorylation GO:0046777 9.62 BTK KDR KIT NTRK3
10 pigmentation GO:0043473 9.61 ATP7A KIT
11 ovarian follicle development GO:0001541 9.61 KIT KITLG
12 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.61 CCL5 KDR KIT
13 cellular response to fibroblast growth factor stimulus GO:0044344 9.6 CCL2 CCL5
14 lipopolysaccharide-mediated signaling pathway GO:0031663 9.59 CCL2 CCL5
15 positive regulation of Ras protein signal transduction GO:0046579 9.57 KITLG RASGRP4
16 positive regulation of JAK-STAT cascade GO:0046427 9.56 CCL5 KIT
17 peptidyl-tyrosine phosphorylation GO:0018108 9.56 BTK KDR KIT NTRK3
18 MAPK cascade GO:0000165 9.55 CCL2 CCL5 KIT KITLG RASGRP4
19 positive regulation of nitric-oxide synthase biosynthetic process GO:0051770 9.54 CCL2 KDR
20 protein kinase B signaling GO:0043491 9.54 CCL2 CCL5 KDR
21 macrophage chemotaxis GO:0048246 9.52 CCL2 CCL5
22 positive regulation of positive chemotaxis GO:0050927 9.51 KDR NTRK3
23 ectopic germ cell programmed cell death GO:0035234 9.49 KIT KITLG
24 embryonic hemopoiesis GO:0035162 9.13 KDR KIT KITLG
25 transmembrane receptor protein tyrosine kinase signaling pathway GO:0007169 9.02 BTK KDR KIT NTRK3 RASGRP4

Molecular functions related to Mast-Cell Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 kinase activity GO:0016301 9.71 BTK KDR KIT NTRK3
2 cytokine activity GO:0005125 9.54 CCL2 CCL5 KITLG
3 Ras guanyl-nucleotide exchange factor activity GO:0005088 9.5 KIT KITLG RASGRP4
4 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.33 KDR KIT NTRK3
5 signal transducer, downstream of receptor, with protein tyrosine kinase activity GO:0004716 9.26 KDR KIT
6 protein tyrosine kinase activity GO:0004713 9.26 BTK KDR KIT NTRK3
7 protein kinase activity GO:0004672 9.1 BTK CCL2 CCL5 KDR KIT NTRK3

Sources for Mast-Cell Leukemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....